[Urogenital estrogen deficiency syndrome. Investigation and treatment with special reference to hormone substitution].
The risk of developing urogenital disorders increases after menopause due to decline in oestrogen production in postmenopausal women. Symptoms due to atrophy of the squamous epithelium in the vagina, urethra and bladder, recurrent urinary tract infections and abnormal function of lower urinary tract comprise the urogenital oestrogen-deficiency syndrome. The symptoms are directly related to atrophic changes in the urogenital tract. They cause reduced quality of life and persist lifelong if not treated. The present review discusses the incidence, symptoms, pathogenesis and treatment of this syndrome. Substitution therapy with oestriol is effective and has no metabolic effects or serious side effects at the recommended dosage. Oestriol should be used lifelong. The syndrome is underreported and undertreated in Norway. Therefore, an evaluation of the general health condition of elderly women, should include direct questions about these symptoms, and oestriol treatment should be offered liberally. It is effective, safe and cost-effective.
Eriksen
B C
BC
Kvinneklinikken, Regionsykehuset i Trondheim.
Hunskår
S
S
D000368:Aged; D001284:Atrophy; D004964:Estriol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy / Q000191:economics; D004967:Estrogens / Q000172:deficiency*; D005260:Female; D052776:Female Urogenital Diseases / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D013577:Syndrome
D004967:Estrogens; D004964:Estriol
Urogenital østrogenmangel-syndrom. Utredning og behandling med vekt på hormonsubstitusjon.